Translational Study Of The Genetics Of Systemic Autoimmunity Based On Mouse Mutagenesis
Funder
National Health and Medical Research Council
Funding Amount
$518,500.00
Summary
Lupus is the prototypic autoimmune disease. It is characterised by inflammation that can damage virtually any organ in the body. This inflammation is the outcome of a complex interplay between the environment and genetic predisposition, resulting in production of antibodies against components of normal tissue. Better characterisation of the genetic basis of lupus is a priority because it is the single best path towards a clearer understanding of the mechanism of this debilitating disease, and ul ....Lupus is the prototypic autoimmune disease. It is characterised by inflammation that can damage virtually any organ in the body. This inflammation is the outcome of a complex interplay between the environment and genetic predisposition, resulting in production of antibodies against components of normal tissue. Better characterisation of the genetic basis of lupus is a priority because it is the single best path towards a clearer understanding of the mechanism of this debilitating disease, and ultimately, new therapeutic options. Strategies used to identify the genetic basis of human disease fall into two categories. The first involves gathering genetic information from families with more than one affected member, which is then compared with genetic information from unaffected people. This can identify genetic regions likely to contain disease-causing genes, but so far, this approach has met with limited success in lupus. Although regions of the genome that harbour disease-associated genes have been found, few actual disease causing genes have been confirmed. The second approach begins with known genes that might plausibly cause the disease, based on prior knowledge then tests are performed to see whether particular variants of these genes are more common in patients than in healthy controls. Obviously this approach is usually biased towards investigation of candidate genes that are already well-characterised. In this project, we will combine information obtained from a large-scale mouse-based programme in which genetic changes that cause features of lupus are generated randomly. In other words, there is an unbiased search for candidate genes, which should lead to the discovery of new disease pathways. Since the mouse and human immune systems are remarkably similar, genetic abnormalities that cause features of lupus in mice are highly likely to be informative about the genetic basis of human lupus, a hypothesis we will test with genetic studies in humans with lupus.Read moreRead less
How BANK1 Pathway Defects In B Cells Cause Human Lupus
Funder
National Health and Medical Research Council
Funding Amount
$1,316,839.00
Summary
Autoimmune diseases affect 1 in 20 Australians and are incurable. To find effective therapies, we need to understand the genes that cause disease in humans. We have sequenced the entire genome of patients with an autoimmune disease and found several patients carrry two mutations in genes important for activation of B cells and shown these mutations cause disease. We plan to understand how these genes prevent autoimmunity, and to identify the best treatment for patients with these mutations.
Immune Balance-regulating Interleukins As Targets For Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The immune balance is crucial to human health. Interleukins are a group of proteins secreted by immune cells to mediate their communication. They tune up or down immune responses, thus as attractive targets for immunotherapy to restore the immune balance to treat autoimmune diseases, allergies and infections. This fellowship will support translational research to develop Interleukin-2 (IL-2) and IL-21-based novel immunotherapies for autoimmune disease, infection and allergy.
Molecular Signatures Of Public Clonotypes In Human Systemic Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$540,633.00
Summary
New platform technology has been developed to study autoantibody clones in lupus and Sjogren's syndrome. This approach has furthered our understanding of these disorders by the discovery of unique sets of clones that are common to all patients. The unique "molecular signatures" of these clones can be translated to a next-generation diagnostic that detects them in patients at extremely low levels missed by conventional tests.
Regulation Of Autoimmunity By Non-apoptotic Caspases
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Excessive cell death can lead to chronic inflammation and autoimmunity. Cells can die by different mechanisms including necroptosis which causes inflammation, and apoptosis which does not. Recent studies show that caspases, a component of the apoptosis pathway which accelerate cell death, also prevent immune activation by dying cells. I will investigate whether caspases contribute to autoimmune disease and whether caspases can dampen the inflammation that occurs during necroptotic cell death.
Systemic lupus erythematosus (SLE) is a condition which causes inflammation in many different organs and can lead to significant suffering and death. Glucocorticoids (GC) are very good at controlling inflammation, however they have severe side effects such as diabetes and bone thinning, and cannot be used long term. This project aims to investigate a protein “GILZ” in patients with SLE. GILZ may have similar anti-inflammatory effects to GC but may not be associated with the same side effects.
Development Of A Safer New Treatment For Systemic Lupus Erythematosus That Preserves B Cell Immunity
Funder
National Health and Medical Research Council
Funding Amount
$672,008.00
Summary
Lupus is an illness characterized by the body’s immune system attacking the body itself. More than 5 millions of people worldwide suffer from lupus, in particular Indigenous Australians who are 4 times more likely to develop lupus. Current treatments are toxic and/or lack efficacy. In this proposal we use strong new evidence from the laboratory to support the design of a much safer and more effective treatment for lupus that will be validated for future use in patients.
This project introduces a new biomarker in systemic lupus erythematosus termed an apotope. The aims are to study the diagnostic potential of an apotope of Ro60, a key target in lupus, together with its ability to initiate the disease and cause organ damage. The interaction of the Ro60 apotope with a novel protective factor called beta2-glycoprotein I will also be studied. These discoveries are likely to lead to new diagnostic tests and preventions for lupus and neonatal lupus.
Rogue B Cell Clones In Patients With Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$916,670.00
Summary
Our immune system protects us from disease by producing antibodies. However, 5% of Australians suffer from an autoimmune disease where they produce “auto” antibodies, which attack their own organs. This research will study the cells (termed B cells) responsible for making autoantibodies to determine how they differ from B cells that defend against disease. The goal is to develop therapies that eliminate autoantibody producing B cells from patients while preserving the immune system.